Dexcom (NSDQ:DXCM) announced today that it received CE Mark approval in Europe for its G6 continuous glucose monitoring system. The Dexcom G6 uses a small, wearable sensor and transmitter, now indicated to be placed on the back of the upper arm, to continuously measure and send glucose levels wirelessly to a dedicated receiver or compatible smart […]
Insulet resumes next-gen Omnipod pivotal study following software issues
Insulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly. The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential […]
Livongo announces $400m offering
Livongo Health (NSDQ:LVGO) announced that it intends to offer $400 million in a private offering of convertible senior notes. Mountain View, Calif.-based Livongo also plans to grant the initial purchasers of the notes, due in 2025, a 13-day option to purchase up to an additional $60 million, according to a news release. The notes will be […]
FDA clears Welldoc diabetes software
Welldoc announced today that it received FDA clearance for an additional feature of its BlueStar Rx software for users of long-acting insulin. Patients with diabetes who are prescribed the insulin adjustment program (IAP) as part of BlueStar can now receive real-time adjustments to their insulin with the newly cleared feature, according to a news release. […]
Bigfoot Biomedical raises $55m in Series C
Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round. Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management. Milpitas, Calif.-based Bigfoot said in a news release that […]
Dexcom completes sale of $1.05B in notes
Dexcom (NSDQ:DXCM) announced that it completed the sale of $1.05 billion aggregate principal amount of its convertible senior notes. The San Diego-based continuous glucose monitoring system developer announced earlier this week that it was offering $850 million in notes with plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate […]
Insulet prices $500m public offering
Insulin management technology developer Insulet (NSDQ:PODD) announced that it priced a $500 million common stock offering. The Acton, Mass.-based company set the price of its common stock at $211 per share, with more than 2.3 million shares set to be sold. Insulet also granted underwriters a 30-day option to purchase up to 355,450 additional shares. Morgan […]
DexCom prices $1.05B ‘upsized’ offering
Continuous glucose monitoring system developer Dexcom (NSDQ:DXCM) announced today that it priced an upsized offering worth $1.05 billion in convertible senior notes. Yesterday, the San Diego-based company announced an offering worth $850 million with plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of notes. Today, […]
Tandem Diabetes Care announces $250m offering
Tandem Diabetes Care (NSDQ:TNDM) announced today that it intends to offer a private placement worth $250 million in convertible senior notes. The convertible senior notes, due in 2025, will be senior unsecured obligations of Tandem and are set to accrue interest payable semiannually in arrears, according to a news release. San Diego-based Tandem also intends to […]
Dexcom to raise $850m from senior notes offering
Dexcom (NSDQ:DXCM) said today that it plans to offer an $850 million aggregate principal amount of convertible senior notes due 2025. The San Diego-based continuous glucose monitoring systems company also plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of notes. Dexcom plans to use $600 […]
Insulet posts mixed bag Q1
Insulet (NSDQ:PODD) shares dropped slightly today on first-quarter results that topped the consensus revenue forecast but came up short on earnings. The Acton, Mass.-based insulin management technology developer posted losses of -$2.1, or -3¢ per share, on sales of $198 million for the three months ended March 31, 2020, for a bottom-line slide into losses from […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 94
- Next Page »
